mTORC1 and DNA-PKcs as Novel Molecular Determinants of Sensitivity to Chk1 Inhibition

Chk1 inhibitors are currently under clinical evaluation as single agents and in combination with cytotoxic chemotherapy. Understanding determinants of sensitivity and novel combinations is critical for further clinical development.

Source: Molecular Oncology - August 25, 2015 Category: Cancer & Oncology Authors: Andrew J. Massey, Peter Stephens, Rebecca Rawlinson, Lauren McGurk, Ruth Plummer, Nicola J. Curtin Source Type: research